Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OX40L monoclonal antibody

            Therapeutic Area: Immunology Product Name: KY1005

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $1,450.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition April 09, 2021

            Details:

            Sanofi gains Kymab's KY1005 to its pipeline, a fully human monoclonal antibody targeting key immune system regulator OX40L. Kymab’s pipeline also includes the oncology asset KY1044.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NT-0167

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novo Holdings

            Deal Size: $55.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing June 03, 2020

            Details:

            Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of NT-0167 through clinical development.